Unichem receives ANDA approval for quetiapine extended-release tablets
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD)
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD)
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Man lost 54 Kgs in 6 months with MGB procedure
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
The product will be manufactured at Lupin’s facility in Goa, India.
Subscribe To Our Newsletter & Stay Updated